X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with ASTRAZENECA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs ASTRAZENECA PHARMA - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS ASTRAZENECA PHARMA NOVARTIS/
ASTRAZENECA PHARMA
 
P/E (TTM) x 347.8 93.7 371.4% View Chart
P/BV x 17.1 13.3 128.4% View Chart
Dividend Yield % 1.7 0.0 -  

Financials

 NOVARTIS   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-16
ASTRAZENECA PHARMA
Mar-14
NOVARTIS/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs9821,285 76.4%   
Low Rs556634 87.7%   
Sales per share (Unadj.) Rs252.9189.6 133.4%  
Earnings per share (Unadj.) Rs62.1-0.2 -30,522.3%  
Cash flow per share (Unadj.) Rs63.33.8 1,646.3%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs363.668.6 529.7%  
Shares outstanding (eoy) m31.9625.00 127.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.05.1 60.1%   
Avg P/E ratio x12.4-4,712.7 -0.3%  
P/CF ratio (eoy) x12.2249.6 4.9%  
Price / Book Value ratio x2.114.0 15.1%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m24,58023,988 102.5%   
No. of employees `0000.81.6 48.2%   
Total wages/salary Rs m1,8011,605 112.3%   
Avg. sales/employee Rs Th10,748.93,040.2 353.6%   
Avg. wages/employee Rs Th2,395.21,029.2 232.7%   
Avg. net profit/employee Rs Th2,641.1-3.3 -80,893.1%   
INCOME DATA
Net Sales Rs m8,0834,740 170.5%  
Other income Rs m82992 900.5%   
Total revenues Rs m8,9134,832 184.5%   
Gross profit Rs m234-130 -180.4%  
Depreciation Rs m37101 36.3%   
Interest Rs m20-   
Profit before tax Rs m1,025-139 -738.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m170-   
Extraordinary Inc (Exp) Rs m1,696139 1,221.2%   
Tax Rs m7525 14,774.1%   
Profit after tax Rs m1,986-5 -39,019.6%  
Gross profit margin %2.9-2.7 -105.8%  
Effective tax rate %73.4-3.7 -2,001.9%   
Net profit margin %24.6-0.1 -22,879.8%  
BALANCE SHEET DATA
Current assets Rs m12,6782,726 465.0%   
Current liabilities Rs m2,4332,435 99.9%   
Net working cap to sales %126.76.1 2,061.5%  
Current ratio x5.21.1 465.4%  
Inventory Days Days3374 44.3%  
Debtors Days Days2241 55.2%  
Net fixed assets Rs m691,035 6.7%   
Share capital Rs m16050 319.6%   
"Free" reserves Rs m11,460942 1,216.0%   
Net worth Rs m11,6211,716 677.2%   
Long term debt Rs m00-   
Total assets Rs m14,4004,156 346.5%  
Interest coverage x570.5NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.61.1 49.2%   
Return on assets %13.8-0.1 -11,272.1%  
Return on equity %17.1-0.3 -5,761.6%  
Return on capital %23.60-  
Exports to sales %0.75.7 13.1%   
Imports to sales %18.66.5 287.7%   
Exports (fob) Rs m60270 22.3%   
Imports (cif) Rs m1,503306 490.6%   
Fx inflow Rs m186375 49.7%   
Fx outflow Rs m1,821470 387.3%   
Net fx Rs m-1,635-96 1,710.6%   
CASH FLOW
From Operations Rs m2,531-8 -31,245.7%  
From Investments Rs m-8,270-146 5,675.8%  
From Financial Activity Rs m-386862 -44.7%  
Net Cashflow Rs m-6,125709 -864.4%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 75.0 100.0%  
Indian inst/Mut Fund % 2.0 0.3 666.7%  
FIIs % 1.6 15.7 10.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 9.1 236.3%  
Shareholders   41,647 12,856 323.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   STERLING BIOTECH  SANOFI INDIA  PANACEA BIOTECH  ORCHID PHARMA LTD  GSK PHARMA  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Aug 18, 2017 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS